Prevention & lipidsCohort study
Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3 silencing and predicts clinically relevant coronary heart disease event reductions
- Genetic modelling study (polygenic score-based cohort analysis)
- UK Biobank
Authors' conclusion
Based on our genetic modelling, the degree of TRL/remnant lowering seen on APOC3 silencing would produce a meaningful CHD risk reduction of around 25 % over a 5-year outcomes trial.
Study context
- Population
- UK Biobank individuals selected by a TRL/remnant-specific polygenic score (PGS)each group >4,150
- Exposure
- Low vs high TRL/remnant-specific PGS
- Outcome
- CHD event rates
- Follow-up
- Lifetime
Main finding
Lifetime CHD event rate
Hazard ratio
0.72
95% CI 0.56–0.91
Low PGS vs High PGS
HR 0.72 (95% CI 0.56–0.91)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Lipid differences, low vs high PGS
- Plasma TG
- −34%
- TRL/remnant cholesterol
- −22.5%
- Non-HDL cholesterol
- −7.5%
- Apolipoprotein B
- −6.0%
- LDL cholesterol
- −3.9%
- HDL cholesterol increase
- 15.3%
- similar to APOC3 silencing agents, about a third of the absolute effect size
Predicted coronary heart disease (CHD) risk reduction, 5-year trial extrapolation
- APOC3 silencing agent with 16-23 mg/dL TRL/remnant cholesterol decrease: predicted CHD risk reduction
- approximately 25%
Original publication
Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3 silencing and predicts clinically relevant coronary heart disease event reductions. Eur J Prev Cardiol. Published 14 October 2025. doi:10.1093/eurjpc/zwaf657
Summarised from the published abstract; every number is checked against it